Design, development and evaluation of amlodipine besylate solid lipid nanopaticles

Pavithra Evangeline; K Manjunath; Prajwal Y

Design, development and evaluation of amlodipine besylate solid lipid nanopaticles

Authors
Pavithra Evangeline, K Manjunath, Prajwal Y

Abstract
The aim of the present study is to develop Amlodipine Besylate solid lipid nanoparticles and to evaluate them. Recently, solid lipid nanoparticles have gained much attention of the researchers due to its reduced toxicity, improved stability. Amlodipine Besylate solid lipid nanoparticles were prepared by hot homogenization technique for the treatment of angio vascular disease. Amlodipine Besylate is a second generation angio selective calcium channel blocker. The design of Amlodipine Besylate solid lipid nanoparticles and their evaluation which would attenuate the problems associated with the oral administration of Amlodipine Besylate, and also easy to maintain the constant drug level in the blood. Amlodipine Besylate solid lipid nanoparticles were prepared by hot homogenization technique using different lipids (Tristearin, Glycerol monostearate and Compritol 888), soy lecithin used as a stabilizer and (tween 80, poloxamer-188) chosen as surfactants. The nanoparticles were evaluated for particle size & PDI, zeta potential, entrapment efficiency and in vitro drug release. The particle size ranged from 96.37 to 812.2nm. PDI of all formulations were good within the range of 0.015 to 0.576. The zeta potential of blank SLN was -15.2 mV whereas drug loaded SLN showed zeta potential from -3.19 mV to -45.8mV. Entrapment efficiency observed was in the range of 82 to 95 %. The cumulative percentage release of Amlodipine Besylate from different Amlodipine Besylate nanoparticles varied from 66 to 82 % depending upon the drug-lipid ratio and the type of lipid and surfactant used. The release kinetic studies showed that the release was First order and the release mechanism was non-Fickian type.

Download | Pages : 19-25